TiGenix Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 89
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $617M
Latest Deal Amount

TiGenix General Information

Description

TiGenix NV is a biopharmaceutical company. It exploits anti-inflammatory properties of stem cells to develop therapies from its proprietary technology platforms for serious medical conditions in the areas of high unmet medical need. The firm's product candidates include Cx601, Cx611, and AlloCSC-01. The firm's products target automimmune, inflammatory and heart diseases. It has Biopharmaceutical operating segment.

Contact Information

Website
www.tigenix.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Romeinse straat 12/2
  • 3001 Leuven
  • Belgium
+32 016 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TiGenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 04-Jan-2018 $617M 00000 00000 Completed Generating Revenue
14. Secondary Transaction - Open Market 13-Oct-2017 00000 Completed Profitable
13. 2PO 15-Dec-2016 000.00 00000 00000 Completed Profitable
12. PIPE 05-Jul-2016 0000 00000 Completed Profitable
11. PIPE 10-Mar-2016 000.00 00000 Completed Profitable
10. PIPE 25-Nov-2015 00.00 00000 Completed Profitable
9. Debt - General 23-Dec-2013 000.00 00000 Completed Profitable
8. PIPE 19-Nov-2013 000.00 00000 Completed Profitable
7. PIPE 20-Dec-2012 $8.73M $120M Completed Profitable
6. Grant 23-Dec-2011 $3.84M $111M Completed Profitable
To view TiGenix’s complete valuation and funding history, request access »

TiGenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
TiGenix NV is a biopharmaceutical company. It exploits anti-inflammatory properties of stem cells to develop therapies f
Biotechnology
Leuven, Belgium
89 As of 2017
00000
0000 0000-00-00
000000&0 00000

00000000

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000

0000000

n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TiGenix Competitors (86)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
0000000 Corporation London, Canada 00 000.00 00000000 000.00
000000 00000000 Venture Capital-Backed Durham, NC 00 000.00 0000000000 000.00
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
You’re viewing 5 of 86 competitors. Get the full list »

TiGenix Executive Team (7)

Name Title Board Seat Contact Info
Wilfried Dalemans Ph.D Chief Technical Officer
Marie Richard MD Chief Medical Officer
You’re viewing 2 of 7 executive team members. Get the full list »

TiGenix Board Members (11)

Name Representing Role Since
Dirk Büscher Ph.D Self Board Member 000 0000
Dirk Reyn Self Board Member 000 0000
Eduard Enrico Holdener MD Self Board Member 000 0000
Jean Stephenne Self Chairman & Independent Director 000 0000
Russell Greig Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

TiGenix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TiGenix Former Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
4BIO Capital Partners Venture Capital Minority 000 0000 000000 0
Auriga Partners (Paris) Venture Capital Minority 000 0000 000000 0
BIP Capital Partners PE/Buyout Minority 000 0000 000000 0
BNP Paribas Fortis Private Equity Growth/Expansion Minority 000 0000 000000 0
Baekeland Fonds II Corporation Minority 000 0000 000000 0
You’re viewing 5 of 23 investors. Get the full list »

TiGenix Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000000 31-Jul-2015 000000000000000000 00000 Pharmaceuticals 0000000 00000
00000000 05-May-2011 000000000000000000 000.00 Medical Supplies
00000000 25-Aug-2010 0000 00000 00.000 Drug Discovery 00000000 00000000 00.0
OrthoMimetics 16-Nov-2009 Merger/Acquisition 000.00 Biotechnology
To view TiGenix’s complete investments and acquisitions history, request access »

TiGenix Subsidiaries (1)

Company Name Industry Location Founded
000000000000 Pharmaceuticals Madrid, Spain 0000
To view TiGenix’s complete subsidiaries history, request access »

TiGenix Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000000 25-Aug-2010 0000 00000 00.000 Completed
  • 10 buyers
To view TiGenix’s complete exits history, request access »